Modeling Niemann–Pick disease type C in a human haploid cell line allows for patient variant characterization and clinical interpretation

  1. Evgueni A. Ivakine1
  1. 1Program in Genetics and Genome Biology, The Hospital for Sick Children Research Institute, Toronto, Ontario, M5G 0A4, Canada;
  2. 2Department of Molecular Genetics, University of Toronto, Toronto, Ontario, M5S 1A8, Canada;
  3. 3Department of Pediatrics, University of Toronto and The Hospital for Sick Children, Toronto, Ontario, M5G 1X8, Canada
  • Corresponding author: zhenya.ivakine{at}sickkids.ca
  • Abstract

    The accurate clinical interpretation of human sequence variation is foundational to personalized medicine. This remains a pressing challenge, however, as genome sequencing becomes routine and new functionally undefined variants rapidly accumulate. Here, we describe a platform for the rapid generation, characterization, and interpretation of genomic variants in haploid cells focusing on Niemann–Pick disease type C (NPC) as an example. NPC is a fatal neurodegenerative disorder characterized by a lysosomal accumulation of unesterified cholesterol and glycolipids. In 95% of cases, NPC is caused by mutations in the NPC1 gene, for which more than 200 unique disease-causing variants have been reported to date. Furthermore, the majority of patients with NPC are compound heterozygotes that often carry at least one private mutation, presenting a challenge for the characterization and classification of individual variants. Here, we have developed the first haploid cell model of NPC. This haploid cell model recapitulates the primary biochemical and molecular phenotypes typically found in patient-derived fibroblasts, illustrating its utility in modeling NPC. Additionally, we show the power of CRISPR/Cas9-mediated base editing in quickly and efficiently generating haploid cell models of individual patient variants in NPC. These models provide a platform for understanding the disease mechanisms underlying individual NPC1 variants while allowing for definitive clinical variant interpretation for NPC.

    Footnotes

    • Received March 20, 2019.
    • Accepted November 1, 2019.

    This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (see http://genome.cshlp.org/site/misc/terms.xhtml). After six months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/.

    | Table of Contents

    Preprint Server